Abx Developability desk

Site licence · quote on request · not a self-serve seat

For biologics CMC and antibody engineering

Which of these numbers can travel to another lab?

A sequence goes in. A protocol-stamped report comes out: the measured cross-lab verdict for each assay, the sequence liabilities, and the clinical non-finding. Abx does not invent an aggregate developability score, and it does not predict immunogenicity.

Portable
HIC ρ 0.968, SMAC ρ 0.923, HAC ρ 0.919. AC-SINS pH 7.4 ρ 0.890, with caution.
Does not travel
Tm2 ρ −0.061 (n=104). Titer ρ 0.325 (n=129). Do not compare those numbers across sites.
Not a prediction
Polyreactivity joined to clinical %ADA gave AUC 0.356. The interval includes chance. That result stays a non-finding.

Build a stamped report

Three worked examples are loaded locally. Nothing is sent until you ask for the stamp. Customer sequences belong on a private site licence, not on this public desk.

What the check is for

One site. One annual licence. About $100,000.

The buyer is a VP or Head of Biologics CMC, or a VP of Antibody Engineering, at a mid-size biotech, a biosimilar developer, or a biologics CDMO. The economic argument is one avoided non-portable Tm decision, or one clone the panel should not have advanced, inside a campaign that already costs millions.

List price for the private desk is USD 100,000 per year for one development site: the stamped report, the calibration tables, three programme reviews, and a private deployment so candidate sequences stay off this public page. A paid pilot can come first. This page does not take a card.

Ask for a site-licence evaluation